3rd Patient Group Being Enrolled in Trial of Fabry Gene Therapy ST-920

3rd Patient Group Being Enrolled in Trial of Fabry Gene Therapy ST-920

310658

3rd Patient Group Being Enrolled in Trial of Fabry Gene Therapy ST-920

A Phase 1/2 clinical trial of Sangamo Therapeutics’ experimental gene therapy ST-920 in people with Fabry disease has completed dosing in second patient group, the company announced in a press release. Based on initial safety data, a trial monitoring committee has recommended that a planned third patient group — testing ST-920 at a higher dose —begin the single-infusion treatment, and patient enrollment is underway. The open-label STAAR study (NCT04046224) is recruiting a total of 48 patients of…

You must be logged in to read/download the full post.